本研究通过观察人脐带间充质干细胞(hUCMSC)对脊柱关节炎(SpA)患者外周血T细胞产生IL-17的抑制作用,初步探索hUCMSC在SpA治疗领域的应用前景.体外分离SpA患者及健康志愿者外周血单个核细胞(PBMNC),PBMNC单独培养或与hUCMSC共培养,应用流式细胞仪检测T细胞中CD3+ CD4+ IL-17+(Th17)及CD3+ γδTCR+ IL-17+细胞比例；应用ELISA检测细胞培养上清中IL-17的浓度.结果表明,SpA患者外周血T细胞中Th17细胞占(3.42±0.82)％,CD3+ γδTCR+ IL-17+细胞占(0.30±0.10)％,分别是健康对照组(0.75±0.25)％和(0.06±0.02)％的4.5倍及5倍(P＜0.01)；SpA患者PBMNC与hUCMSC共培养后,T细胞中Th17细胞下降为(1.81±0.59)％,CD3+ γδTCR+ IL-17+细胞下降为(0.16±0.06)％(P＜0.01)；ELISA检测结果表明,SpA患者PBMNC培养上清IL-17的浓度显著高于健康对照组[(573.95±171.68) pg/ml vs(115.53±40.41) pg/ml (P＜0.01)];SPA患者PBMNC与hUCMSC共培养后,细胞上清IL-17的浓度下降至(443.20±147.94) pg/ml(P＜0.01).结论:hUCMSC能够抑制SpA患者外周血T细胞产生IL-17,在SpA临床治疗中具有应用前景.%In this study, the inhibitory effect of human umbilical cord-derived mesenchymal stem cells (hUCMSC) on interleukin-17(IL-17) production in peripheral blood T cells from patients with spondyloarthritis (SpA) were investigated, in order to explore the therapeutic potential of hUCMSC in the SpA. Peripheral blood mononuclear cells (PBMNC) were isolated from patients with SpA(n = 12) and healthy subjects(n =6). PBMNC were cultured in vitro with hUCMSC or alone. The expression of IL-17 in CD4+ T cells or γ/δ T cells were determined in each subject group by flow cytometry. IL-17 concentrations in PBMNC culture supernatantes were measured by ELISA. The results indicated that the proportion of IL-17-producing CD4+ T cells and IL-17-producing γ/δ T cells of SpA patients were 4.5 folds and 5 folds of healthy controls[CD3 +CD4+ IL-17+ cells (3.42 ±0.82)% vs (0.75 ±0.25)% , P<0.01; CD3 + γ8TCR + IL-17 + cells (0.30 ±0. 10) % vs (0.06 ±0.02) % , P<0.01]. After co-culture of PBMNC in patients with hUCMSC, the increased proportions of CD3+ CD4 + IL-17+ cells and CD3 + 78TCR+ IL-17+ cells in SpA patients were inhibited significantly by hUCMSC[CD3+CD4+ IL-17+ cells (3.42±0.82)% vs (1.81 ±0.59)% (P<0.01); CD3+ 78TCR+ IL-17+ cells (0.30±0. 10)% vs (0.16 ±0.06)% (P<0.01]. In response to phytohemagglutinin (PHA, μg/ml), PBMNC from SpA patients secreted more IL-17 than that from healthy control [ (573. 95 ± 171. 68) pg/ml vs (115.53 ±40.41) pg/ml (P<0.01)]. In the presence of hUCMSC, PBMNC of SpA patients produced less amount of IL-17 [ (573.95 ± 171.68)pg/ml vs (443.20 ±147.94) pg/ml, (P<0.01)]. It is concluded that the IL-17 production in peripheral blood T cells from SpA patients can be inhibited by hUCMSC, which have therapeutic potential for SpA.
展开▼
